Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
H. Lundbeck A/S is a Danish multinational pharmaceutical company specializing in the research, development, manufacturing, and commercialization of innovative therapies for brain diseases. Founded in 1915 and headquartered in Valby, Denmark, it focuses exclusively on psychiatric and neurological disorders, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease, epilepsy, and migraine. With over 70 years of neuroscience expertise, the company operates in more than 50 countries, employs around 5,700 people, and maintains research centers in Denmark and the US, plus production facilities in Denmark, France, and Italy. Key strategic brands such as Rexulti, Vyepti, Abilify Maintena, Brintellix, and Asimtufii drive its revenue, achieving record sales of DKK 22,004 million in 2024 through strong growth in major markets like the US, Europe, China, and Japan. Lundbeck's 'Focused Innovator Strategy' emphasizes neuro-rare and specialist-treated diseases, bolstered by acquisitions like Longboard Pharmaceuticals and significant R&D investments projected at DKK 5.0-5.2 billion in 2025. As a leader in brain health, it advances patient outcomes worldwide via a robust pipeline and global distribution network.